Since IL-6/IL-6R signaling is known to act in a number of ways to augment cancer progression, we examined whether the exogenous treatment of IL-6 enhances proliferation, invasion and VEGF-related angiogenesis in ovarian cancer cells. This evidence concerns the gene IL6R and ovarian carcinoma.